The molecular genetics of endocrine tumours

Journal of Pediatric Endocrinology and Metabolism

Volumn 11, Issue 2, 1998, Pages 195-228

  Learoyd, Diana L ^a,b   Twigg, Stephen M ^a,b   Zedenius, Jan V ^c   Robinson, Bruce G ^a,b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA REPAIR; ENDOCRINE TUMOR; GENETIC PREDISPOSITION; GENETIC REGULATION; HORMONAL REGULATION; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE; PRIMARY HYPERPARATHYROIDISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

EID: 0031917325     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1998.11.2.195     Document Type: Review

References (206)

1. Santoro M, Carlomagno F, Romano A, Boltaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-383.
2. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995; 15: 1613-1619.
3. Spada A, Vallar L, Faglia G. Cellular alterations in pituitary tumors (review). Eur J Endocrinol 1994; 130: 43-52.
4. Thakker RV, Pook MA, Wooding C, Boscaro M, Scanarini M, Clayton RN. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J Clin Invest 1993; 91: 2815-2821.
5. Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering MB, Weinstein LS, McBride WO, Nakamura Y, Brandi ML, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1 [published erratum appears in N Engl J Med 1989; 321: 1057]. N Engl J Med 1989; 321: 213-218.
6. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-67.
7. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmertbuck MR, Debelenko LV, Zhuang ZP, Lubensky IA, Liotta LA, Crabtree JS, Wang YP, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong QH, Spiegel AM, Burns AL, Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407.
8. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995; 5: 407-424.
9. Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, Larsson C, Backdahl M. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 1996; 56: 4219-4223.
10. Trupp M, Arenas E, Fainzilber M, Nilsson A-S, Sieber B-A, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U, Sariola H, Saarma M, Ibanez CF. Functional receptor for GDNF encoded by the cret proto-oncogene. Nature 1996; 381: 785-793.
11. Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature 1996; 382: 80-83.
12. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367: 380-383.
13. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G, Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987; 328: 170-172.
14. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-563.
15. Pierotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, Monzini N, Miozzo M, Herrmann MA, Fusco A, Hay ID, Della Porta G, Vecchio G. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992; 89: 1616-1620.
16. Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti MA. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIa of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993; 13: 358-366.
17. Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Blutti MG, Pilotti S, Della Porta G, Pierotti MA. A t(10;17) translocation creates the RET/PTC2 chimeric trans- forming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 1994; 9: 244-250.
18. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994; 9: 509-516.
19. Jhiang SM, Smanik PA, Mazzaferri EL. Development of a single-step duplex RT-PCR detecting different forms of ret activation, and identification of the third form of in vivo ret activation in human papillary thyroid carcinoma. Cancer Lett 1994; 78: 69-76.
20. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident. Oncogene 1996; 13: 1099-1102.
21. Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 1996; 13: 1093-1097.
22. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papl L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460.
23. Donis Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
24. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91: 1579-1583.
25. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 1994; 3: 237-241.
26. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-376.
27. Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC. Catalytic specificity of protein tyrosine kinases is critical for selective signalling. Nature 1995; 373: 536-539.
28. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fekete C, Ponder BAJ, Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367: 378-380.
29. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M, Kaariainen H, Martucciello G. Point mutations affecting the tyrosine kinase domain of the RET proto- oncogene in Hirschsprung's disease. Nature 1994; 367: 377-378.
30. Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosom Cancer 1996; 16: 1-14.
31. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
32. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science 1992; 257: 1258-1261.
33. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang ZP, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
34. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 1995; 55: 1787-1791.
35. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas [see comments]. Nature 1993; 365: 649-651.
36. 2+ cascades. Mol Endocrinol 1995; 9: 725-733.
37. Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 1996; 81: 3898-3901.
38. Matsuo K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab 1993; 76: 1446-1451.
39. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655-659.
40. Horie H, Yokogoshi Y, Tsuyuguchi M, Saito S. Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Jpn J Cancer Res 1995; 86: 737-742.
41. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome [see comments]. N Engl J Med 1991; 325: 1688-1695.
42. McCormick F. Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 1994; 4: 71-76.
43. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterised thyroid nodules. Thyroid 1996; 6: 409-416.
44. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford Thomas D. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988; 48: 4459-4463.
45. Rochefort P, Caillou B, Michiels FM, Ledent C, Talbot M, Schlumberger M, Lavelle F, Monier R, Feunteun J. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene 1996; 12: 111-118.
46. Duh QY, Grossman RF. Thyroid growth factors, signal transduction pathways, and oncogenes. Surg Clin North Am 1995;75:421-437.
47. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B, Joubert D. Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab 1993; 77: 1125-1129.
48. Prevostel C, Alvaro V, de Boisvilliers F, Martin A, Jaffiol C, Joubert D. The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene 1995; 11: 669-674.
49. Pirson I, Coulonval K, Lamy F, Dumont JE. c-Myc expression is controlled by the mitogenic cAMP-cascade in thyrocytes. J Cell Physiol 1996; 168: 59-70.
50. Wynford Thomas D. Molecular basis of epithelial tumorigenesis: the thyroid model. Crit Rev Oncog 1993; 4: 1-23.
51. Vila V, Jimenez O, Guell A, Castrillo JL. Pit-1 and Pit-2 role in growth hormone gene regulation. J Pediatr Endocrinol 1993; 6: 225-228.
52. Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima Y, Byers MG, Shows TB, Kronenberg HM. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989; 83: 2034-2040.
53. Kamb A, Gruis NA, Weaver Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types [see comments]. Science 1994; 264: 436-440.
54. Dinnen JS, Greenwoood RH, Jones JH, Walker DA, Williams ED. Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol 1977; 30: 966-975.
55. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
56. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse [see comments]. Nature 1992; 359: 295-300.
57. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
58. Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci 1995; 20: 426-430.
59. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene [see comments]. N Engl J Med 1993; 329: 1318-1327.
60. Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C, Califano D, Monaco C, Viglietto G, Santoro M, Fusco A. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 1996; 134: 177-183.
61. Goretzki PE, Gorelov V, Dotzenrath C, Witte J, Roeher HD. A frequent mutation/polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer. Surgery 1996; 120: 1081-1088.
62. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
63. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci 1971; 68: 820-823.
64. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 1994; 25: 549-561.
65. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
66. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C [see comments]. Science 1995; 269: 1444-1446.
67. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 10589-10594.
68. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990; 63: 851-859.
69. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7: 353-361.
70. Li Y, Bollag G, Clark R, Stevens J, Conroy L, Fults D, Ward K, Friedman E, Samowitz W, Robertson M, et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 1992; 69: 275-281.
71. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, Mccombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
72. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV. Identification of a candidate tumour suppressor gene, mmac1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
73. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994; 7: 98-102.
74. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852.
75. Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 1992; 75: 1398-1400.
76. Williams ED. Thyroid tumorigenesis. Horm Res 1994; 42: 31-34.
77. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution [editorial]. J Clin Endocrinol Metab 1996; 81: 2783-2785.
78. Hamacher C, Studer H, Zbaeren J, Schatz H, Derwahl M. Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenylate cyclase activity and growth of these tumors [see comments]. J Clin Endocrinol Metab 1995; 80: 1724-1732.
79. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard JA, Caillou B, Monier R, Rapoport B, Filetti S, et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995; 80: 1347-1351.
80. Russo D, Arturi F, Suarez HG, Schlumberger M, Du Villard JA, Crocetti U, Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996; 81: 1548-1551.
81. Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 1994; 79: 657-661.
82. Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, Filetti S. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab 1996; 81: 1898-1904.
83. Oyama T, Suzuki T, Hara F, Iino Y, Ishida T, Sakamoto A, Nakajima T. N-ras mutation of thyroid tumor with special reference to the follicular type. Pathol Int 1995; 45: 45-50.
84. Zedenius J, Wallin G, Svensson A, Grimelius L, Hoog A, Lundell G, Backdahl M, Larsson C. Allelotyping of follicular thyroid tumors. Hum Genet 1995; 96: 27-32.
85. Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991; 73: 832-836.
86. Goretzki PE, Lyons J, Stacy Phipps S, Rosenau W, Demeure M, Clark OH, McCormick F, Roher HD, Bourne HR. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992; 16: 576-581.
87. Herrmann MA, Hay ID, Bartelt DH Jr, Ritland SR, Dahl RJ, Grant CS, Jenkins RB. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest 1991; 88: 1596-1604.
88. Zedenius J, Wallin G, Svensson A, Bovee J, Hoog A, Backdahl M, Larsson C. Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Hum Genet 1996; 97: 299-303.
89. Scheumman GFW, Hoang Vu C, Cetin Y, Gimm O, Behrends J, Vonwasielewski R, Georgii A, Birchmeier W, Vonzurmuhlen A, Dralle H, Brabant G. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 1995; 80: 2168-2172.
90. Brabant G, Hoang Vu C, Cetin Y, Dralle H, Scheumann G, Molne J, Hansson G, Jansson S, Ericson LE, Nilsson M. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 1993; 53: 4987-4993.
91. Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J. Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. Am J Surg 1993; 166: 366-368.
92. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen AL, Auer G. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 1996; 6: 1-9.
93. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994; 123: 331-337.
94. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995; 55: 5617-5620.
95. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995; 11: 2459-2467.
96. Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996; 81: 3360-3365.
97. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N, Akiyama M. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 1993; 53: 2940-2943.
98. Ito T, Seyama T, Iwamoto KS, Mizuno T, Tronko ND, Komissarenko IV, Cherstovoy ED, Satow Y, Takeichi N, Dohi K, Akiyama M. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994; 344: 259.
99. Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED. Ret activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer 1996; 74: 585-589.
100. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81: 2006-2009.
101. Jhiang SM, Caruso DR, Gilmore E, Ishizaka Y, Tahira T, Nagao M, Chiu IM, Mazzaferri EL. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 1992; 7: 1331-1337.
102. Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, Filetti S, Suarez HG. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 1995; 11: 1907-1911.
103. Basolo F, Pinchera A, Fugazzola L, Fontanini G, Elisei R, Romei C, Pacini F. Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur J Cancer 1994; 30A: 171-174.
104. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994; 116: 1010-1016.
105. Zou M, Shi Y, Farid NR. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993; 77: 1054-1058.
106. Simon D, Goretzki PE, Gorelev V, Ebling B, Reishaus E, Lyons J, Haubruck H, Roher HD. Significance of P53 in human thyroid tumors. World J Surg 1994; 18: 535-540.
107. Loh K-C. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997; 7: 107-113.
108. Fagin JA. Familial nonmedullary thyroid carcinoma - the case for genetic susceptibility [editorial]. J Clin Endocrinol Metab 1997; 82: 342-344.
109. Burgess JR, Duffield A, Wilkinson SJ, Ware R, Greenaway TM, Percival J, Hoffman L. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab 1997; 82: 345-348.
110. Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 1994; 79: 1317-1321.
111. Coyle B, Coffey R, Armour JA, Gausden E, Hochberg Z, Grossman A, Britton K, Pembrey M, Reardon W, Trembath R. Pendred syndrome (goitre and sensorineural hearing loss) maps to chromosome 7 in the region containing the nonsyndromic deafness gene DFNB4. Nat Genet 1996; 12: 421-423.
112. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91: 179-184.
113. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, Machinami R. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 1994; 3: 9-14.
114. Pacini F, Pinchera A, Mancusi F, Pollina L, Fontanini G, Bevilacqua G, Miccoli P, Basolo F. Anaplastic thyroid carcinoma - a retrospective clinical and immunohistochemical study. Oncol Rep 1994; 1: 921-925.
115. Capella G, Matias Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 1996; 5: 45-52.
116. Shore RE. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 1992; 131: 98-111.
117. Challeton C, Bounacer A, Du Villard JA, Caillou B, De Vathaire F, Monier R, Schlumberger M, Suarez HG. Pattern of ras and gsp oncogene mutations in radiation- associated human thyroid tumors. Oncogene 1995; 11: 601-603.
118. Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 1996; 13: 687-693.
119. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995; 118: 936-942.
120. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995; 238: 343-346.
121. Eng C, Clayton D, Schuffenecker I, Lenoir GM, Cote GJ, Gagel RF, Ploos van Amstel H, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996; 276: 1575-1579.
122. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994; 3: 1939-1943.
123. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A [see comments]. N Engl J Med 1994; 331: 828-835.
124. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton Bligh P, Robinson BG. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996; 44: 213-220.
125. Learoyd DL, Marsh DJ, Richardson A-L, Twigg SM, Delbridge L, Robinson BG. Genetic testing for familial cancer - consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia type 2. Arch Sur 1997; 132: 1022-1025.
126. Learoyd DL, Capes AG, Robinson BG. Multiple endocrine neoplasia type 2 and glial cell line-derived neurotrophic factor. Curr Opin Endocrinol Diabetes 1997; 4: 130-137.
127. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G. Mutations of codon 918 in the RET proto- oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995; 80: 3088-3090.
128. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 1994; 3: 1259-1262.
129. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81: 1619-1622.
130. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson A-L, Delbridge L, Eng C, Robinson BG. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996; 44: 249-251.
131. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996; 56: 1241-1243.
132. Landsvater RM, de Wit MJ, Zewald RA, Hofstra RMW, Buys CHCM, van Amstel HKP, Hoppener JWM, Lips CJM. Somatic mutations of the RET protooncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res 1996; 56: 853-855.
133. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996; 56: 2167-2170.
134. Wohllk N, Cote GJ, Bugalho MMJ, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF. Relevance of ret proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81: 3740-3745.
135. Sandelin K, Thompson NW, Bondeson L. Metastatic parathyroid carcinoma: dilemmas in management. Surgery 1991; 110: 978-986.
136. Heath H, 3d, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980; 302: 189-193.
137. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcll-linked candidate oncogene [see comments]. Nature 1991; 350: 512-515.
138. Arnold A. Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 1993; 77: 1108-1112.
139. Friedman E, Bale AE, Marx SJ, Norton JA, Arnold A, Tu T, Aurbach GD, Spiegel AM. Genetic abnormalities in sporadic parathyroid adenomas. J Clin Endocrinol Metab 1990; 71: 293-297.
140. Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. Monoclonality and abnormal parathyroid horm- one genes in parathyroid adenomas. N Engl J Med 1988; 318: 658-662.
141. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996; 81: 1736-1739.
142. Tahara H, Smith AP, Gaz RD, Arnold A. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocrinol Metab 1996; 81: 3663-3667.
143. Tahara H, Smith AP, Gas RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 1996; 56: 599-605.
144. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 1320-1324.
145. Hakim JP, Levine MA. Absence of p53 point mutations in parathyroid adenoma and carcinoma. J Clin Endocrinol Metab 1994; 78: 103-106.
146. 2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995; 80: 3107-3110.
147. Komminoth P, Roth J, Mulettafeurer S, Sareaslani P, Seelentag WKF, Heitz PU. Ret proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996; 81: 2041-2046.
148. Padberg BC, Schroder S, Jochum W, Kastendieck H, Roth J, Heitz PU, Komminoth P. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland [see comments]. Am J Pathol 1995; 147: 1600-1607.
149. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996; 81: 2711-2718.
150. Farnebo F, Teh BT, Dotzenrath C, Wassif WS, Svensson A, White I, Betz R, Goretzki P, Sandelin K, Farnebo LO, Larsson C. Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Hum Genet 1997; 99: 342-349.
151. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM, O'Riordan JL. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989; 321: 218-224.
152. Radford DM, Ashley SW, Wells SA Jr, Gerhard DS. Loss of heterozygosity of markers on chromosome 11 in tumors from patients with multiple endocrine neoplasia syndrome type 1. Cancer Res 1990; 50: 6529-6533.
153. Veldhuis JD, Norton JA, Wells SA Jr, Vinik Al, Perry RR. Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. J Clin Endocrinol Metab 1997; 82: 357-364.
154. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nat Genet 1994; 6: 70-74.
155. Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, Yap A, Epstein M, Heath H, Cameron D, Larsson C. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996; 81: 4204-4211.
156. Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995; 56: 944-950.
157. Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ, Larsson C. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993; 77: 1485-1489.
158. Teh BT, Farnebo F, Twigg SM, Hoog A, Kytola S, Grimelius L, Sandelin K, Robinson BG, Farnebo LO, Larsson C. Familial isolated hyperparathyroidism (FIHP) - A new entity or a variant? manuscript in preparation
159. Streeten EA, Weinstein LS, Norton JA, Mulvihill JJ, White BJ, Friedman E, Jaffe G, Brandi ML, Stewart K, Zimering MB, et al. Studies in a kindred with parathyroid carcinoma. J Clin Endocrinol Metab 1992; 75: 362-366.
160. Chou YH, Brown EM, Levi T, Crowe G, Atkinson AB, Arnqvist HJ, Toss G, Fuleihan GE, Seidman JG, Seidman CE. The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nat Genet 1992; 1: 295-300.
161. 2+-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
162. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism [see comments]. Cell 1993; 75: 1297-1303.
163. Marx SJ, Attie MF, Spiegel AM, Levine MA, Lasker RD, Fox M. An association between neonatal primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med 1982; 306: 257-264.
164. Law WM Jr, Heath H 3rd. Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. Ann Intern Med 1985; 102: 511-519.
165. Arnold A, Brown M, Urena P, Gaz R, Drueke T, Sarfati E. X-inactivation analysis of clonality in primary and secondary parathyroid hyperplasia. J Bone Min Res 1997; 7 (Suppl): S153.
166. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicchi P, Bandini S, Marx SJ, Brandi ML. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993; 76: 139-144.
167. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma [see comments]. N Engl J Med 1994; 330: 757-761.
168. Dotzenrath C, Teh BT, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996; 81: 3194-3196.
169. Rubio MP, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993; 53: 3465-3467.
170. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
171. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
172. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
173. Skogseid B, Eriksson B, Lundqvist G, Lorelius LE, Rastad J, Wide L, Akerstrom G, Oberg K. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991; 73: 281-287.
174. Teh BT, McArdle J, Chan SP, Menon J, Hartley L, Pullan P, Ho J, Khir A, Wilkinson S, Larsson C, Cameron D, Shepherd J. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine Baltimore 1997; 76: 21-29.
175. Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B, Ahren B, Kristofferson A, Oberg K, Rastad J, et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992; 16: 611-618.
176. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996; 89: 653-669.
177. Bear JC, Briones Urbina R, Fahey JF, Fand NR. Variant multiple endocrine neoplasia I (MEN IBurin): further studies and non-linkage to HLA. Hum Hered 1985; 35: 15-20.
178. Tordjman K, Stem N, Ouaknine G, Yossiphov Y, Razon N, Nordenskjold M, Friedman E. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 1993; 77: 765-769.
179. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692-696.
180. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 1993; 72: 1386-1393.
181. Williamson EA, Ince PG, Harrison D, Kendall Taylor P, Harris PE. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 1995; 25: 128-131.
182. Dotsch J, Kiess W, Hanze J, Repp R, Ludecke D, Blum WF, Rascher W. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996; 81: 3839-3842.
183. Karga HJ, Alexander JM, Hedley Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992; 74: 914-919.
184. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994; 78: 842-846.
185. Cai WY, Alexander JM, Hedley Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, Klibanski A. ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 1994; 78: 89-93.
186. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol Oxf 1996; 45: 195-200.
187. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995; 55: 1613-1616.
188. Cryns VL, Alexander JM, Klibanski A, Arnold A. The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 1993; 77: 644-646.
189. Schiemann U, Assert R, Moskopp D, Gellner R, Hengst K, Gullotta F, Domschke W, Pfeiffer A. Analysis of a protein kinase c-alpha mutation in human pituitary tumours. J Endocrinol 1997; 153: 131-137.
190. Levy A, Hall L, Yeudall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol Oxf 1994; 41: 809-814.
191. Buckley N, Bates AS, Broome JC, Strange RC, Perrett CW, Burke CW, Clayton RN. p53 protein accumulates in Cushing's adenomas and invasive non-functional adenomas [corrected and republished article originally printed in J Clin Endocrinol Metab 1994; 79: 1513-1516]. J Clin Endocrinol Metab 1995; 80: 4.
192. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997; 11: 433-441.
193. Williamson EA, Johnson SJ, Foster S, Kendall Taylor P, Harris PE. G protein gene mutations in patients with multiple endocrinopathies. J Clin Endocrinol Metab 1995; 80: 1702-1705.
194. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R, Zbar B. Genetic changes in human adrenocortical carcinomas [published erratum appears in J Natl Cancer Inst 1989; 81: 1263]. J Natl Cancer Inst 1989; 81: 518-523.
195. Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 1994; 78: 483-491.
196. Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, Wide L, Wilander E, Oberg K. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992; 75: 76-81.
197. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54: 1298-1304.
198. Wagner J, Portwine C, Rabin K, Leclere JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994; 86: 1707-1710.
199. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993; 54: 408-410.
200. Demeure MJ, Doffek KM, Komorowski RA, Gorski J. Gip-2 codon 179 oncogene mutations: absent in adrenal cortical tumors. World J Surg 1996; 20: 928-931.
201. Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994; 79: 890-893.
202. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van Heerden JA, Thibodeau SN. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 1991; 87: 1691-1699.
203. Vargas MP, Zhuang Z, Wang C, Vortmeyer A, Linehan WM, Merino MJ. Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol 1997; 28: 411-415.
204. Hofstra RMW, Stelwagen T, Stulp RP, Dejong D, Hulsbeek M, Kamsteeg EJ, Vandenberg A, Landsvater RM, Vermey A, Molenaar WM, Lips CJM, Buys CHCM. Extensive mutation scanning of ret in sporadic medullary thyroid carcinoma and of ret and vhl in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996; 81: 2881-2884.
205. Gutmann DH, Geist RT, Rose K, Wallin G, Moley JF. Loss of neurofibromatosis type i (nfi) gene expression in pheochromocytomas from patients without nfi. Genes Chromosom Cancer 1995; 13: 104-109.
206. Zeiger MA, Norton JA. Gs alpha - identification of a gene highly expressed by insulinoma and other endocrine tumors. Surgery 1993; 114: 458-462.